

# Xuedan Zhu

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5044336/publications.pdf>

Version: 2024-02-01

7  
papers

217  
citations

1684188  
5  
h-index

1720034  
7  
g-index

7  
all docs

7  
docs citations

7  
times ranked

99  
citing authors

#	ARTICLE	IF	CITATIONS
1	Progress and challenges of immunotherapy in triple-negative breast cancer. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2021, 1876, 188593.	7.4	106
2	HER2-targeted therapies in gastric cancer. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2021, 1876, 188549.	7.4	76
3	Knockdown of nuclear receptor binding SET domain-containing protein 1 (NSD1) inhibits proliferation and facilitates apoptosis in paclitaxel-resistant breast cancer cells via inactivating the Wnt/ $\beta$ -catenin signaling pathway. <i>Bioengineered</i> , 2022, 13, 3526-3536.	3.2	11
4	Plasma thioredoxin reductase: a potential diagnostic biomarker for gastric cancer. <i>Carcinogenesis</i> , 2022, 43, 736-745.	2.8	8
5	Circulating tumor cells: A surrogate to predict the effect of treatment and overall survival in gastric adenocarcinoma. <i>International Journal of Biological Markers</i> , 2021, 36, 28-35.	1.8	7
6	Nuclear receptor binding SET domain protein 1 promotes epithelial-mesenchymal transition in paclitaxel-resistant breast cancer cells via regulating nuclear factor kappa B and F-box and leucine-rich repeat protein 11. <i>Bioengineered</i> , 2021, 12, 11506-11519.	3.2	5
7	The drugs screened by OncoVee <sup>TM</sup> -Mini-PDX have significantly benefited the patient with HER2-positive advanced gastric cancer. <i>Journal of Oncology Pharmacy Practice</i> , 2022, , 107815522210749.	0.9	4